In gastric cancer, the presence of HER2 gene amplifications is still a controversial issue, where there is no consensus on the frequency of patients presenting these amplifications, due to the difficulty in determining HER2 copy number variation by conventional methodologies (IHC and FISH). This evidence concerns the gene ERBB2 and gastric cancer.